PODCAST: Long-acting injectables: overcoming challenges and implementing best practice
Hear Professors David Castle, John Kane and Philip Gorwood provide expert opinion on crucial aspects of treating patients with schizophrenia and the use of long-acting injectables (LAIs) in practice, including normalising non-adherence, increasing acceptance of LAIs, treating younger male patients, and when and how to initiate therapy.
The views and opinions expressed in this video do not necessarily reflect those of Lundbeck and Otsuka.
Page: AU-ABIM-0581. September 2024. Podcast: AU-ABIM-0540. April 2024.
-
Box AMBody
Abilify Maintena PBS Information: Authority required (STREAMLINED). Code: 4246 for schizophrenia. This product is not listed on the PBS for the treatment of bipolar 1 disorder
-
Text AMBody
Please review Approved Product Information before prescribing.
Product Information is available by calling Lundbeck on 1300 721 277 or by clicking:Abilify Maintena is a registered trademark of Otsuka Pharmaceutical Co., Ltd. Abilify Maintena is co-commercialised by Lundbeck Australia and Otsuka Australia Pharmaceutical Pty Limited.
-
BoxBody
REXULTI PBS Information: Authority required (STREAMLINED). Code: 4246 for schizophrenia
-
TextBody
Please review Approved Product Information before prescribing.
Product Information is available by calling Lundbeck on 1300 721 277 or by clicking:REXULTI® is a registered trademark of H. Lundbeck A/S. REXULTI® is co-commercialised by Lundbeck Australia and Otsuka Australia Pharmaceutical Pty Limited.
